Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy

References

• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29–38.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach JP, et al. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood. 2020;136(8):936–945.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420, doi: 10.1200/JCO.21.02614.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;JCO2102614.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27(10):1037–1043.
   PubMed Web of Science ®Google Scholar
• Ross DM, To LB, Horvath N. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Intern Med J. 2004;34(9–10):576–578.
   PubMed Web of Science ®Google Scholar
• Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025–3031.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Blade J, Mateos M-V, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529–534.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 2008;113(2):355–359.
   PubMed Web of Science ®Google Scholar
• Sidana S, Tandon N, Dispenzieri A, et al. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia. 2019;33(3):730–738.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107(1):121–131.
   PubMed Web of Science ®Google Scholar
• Lahuerta J-J, Paiva B, Vidriales M-B, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900–2910.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Corre J, Lauwers-Cances V, et al. Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial. Blood. 2015;126(23):191–191.
   Google Scholar
• Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18–30.
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464.
   PubMed Web of Science ®Google Scholar
• Bal S, Weaver A, Cornell RF, et al. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. Br J Haematol. 2019;186(6):807–819.
   PubMed Web of Science ®Google Scholar
• Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784–792.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–5999.
   PubMed Web of Science ®Google Scholar
• Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019;33(7):1713–1722.
   PubMed Web of Science ®Google Scholar
• Moreau P, Zweegman S, Perrot A, et al. Evaluation of the prognostic value of Positron Emission Tomography-Computed Tomography (PET-CT) at diagnosis and follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet companion study. Blood. 2019;134(Suppl_1):692–692.
   Google Scholar
• Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report. Blood Cancer J. 2021;11:24.
   PubMed Web of Science ®Google Scholar
• Derman BA. Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd + ASCT. In: Benjamin Avi Derman ATSAMKJTKJJAJJ, University of Chicago Medical Center CIL, Poznan University of Medical Sciences PP, editors 2020; ASCO Virtual Scientific Program. J Clin Oncol. 2020;38(15):8513.
   Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932–1935.
   PubMed Web of Science ®Google Scholar
• Goicoechea I, Puig N, Cedena M-T, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021;137(1):49–60.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324.
   PubMed Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Alonso R, Wong SW, et al. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021;14(1):126.
   PubMed Web of Science ®Google Scholar
• Korde N, Mastey D, Tavitian E, et al. Tailored treatment to MRD response: a phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. Am J Hematol. 2021;96(6):E193–E196.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022;40(25):2901–2912.
   Google Scholar
• Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. The Lancet Haematology. 2021;8(6):e422–e432.
   PubMed Web of Science ®Google Scholar
• Alonso R, Cedena M-T, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020;4(10):2163–2171.
   PubMed Web of Science ®Google Scholar
• Alonso R, Lahuerta JJ. Tumor reduction in multiple myeloma: new concepts for new therapeutics. Front Oncol. 2021;11:800309.
   PubMed Web of Science ®Google Scholar
• Bal S, Costa LJ. Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy. Lancet Haematol. 2021;8(6):e386–e387.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289.
   PubMed Web of Science ®Google Scholar
• Mohan M, Kendrick S, Szabo A, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808–817.
   PubMed Web of Science ®Google Scholar
• Vrabel D, Gregorova J, Sedlarikova L, et al. Tumor specific cfDNA predicts treatment response of multiple myeloma patients. Blood. 2018;132(Suppl 1):3188–3188.
   Google Scholar
• An G, Yan Y, Xu Y, et al. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020;34(2):578–588.
   PubMed Web of Science ®Google Scholar
• Bal S, Chhabra S, Callander NS, et al. Biologic basis of the impact of autologous hematopoietic cell transplantation in multiple myeloma treated with quadruplet therapy. Blood. 2021;138(Suppl 1):483–483.
   Google Scholar
• Anderson KC, Auclair D, Kelloff GJ, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980–3993.
   PubMed Web of Science ®Google Scholar
• Gormley NJ, Turley DM, Dickey JS, et al. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):73–80.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Ludwig H, Landgren O, et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20(1):e30–e37.
   PubMed Web of Science ®Google Scholar